Opthea/OPT

$3.30

-2.94%
-
1D1W1MYTD1YMAX

About Opthea

Opthea Limited is an Australia-based biotechnology company. The Company is engaged in the development and commercialization of therapies primarily for eye disease. The Company’s lead asset, OPT-302, is a novel biologic inhibitor of VEGF-C and VEGF-D, for use in combination with VEGF-A inhibitors for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The Company’s principal activities include the progression of the Company’s Phase III registration trials of OPT-302 for wet AMD. It also manufactures OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. The Company’s development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).

Ticker

OPT

Sector

Healthcare

Trading on

NASDAQ

Industry

Business Services

CEO

Frederic Guerard

Employees

-

Headquarters

Melbourne, Australia
Website
opthea.com

Opthea Metrics

BasicAdvanced
$268.66M
Market cap
-
P/E ratio
-$2.48
EPS
0.62
Beta
-
Dividend rate
$268.66M
0.6175
$4.42
$1.60
22.82K
5.104
-29.64%
-100.84%
-3,383.08%
-116.05%
2,294.319
127.07%
0.81%
22.44%

What the Analysts think about Opthea

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 6 analysts.
283.33% upside
High $15.77
Low $7.89
$3.30
Current price
$12.65
Average price target

Opthea Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q2 24
QoQ growth
Revenue
$0
-
Net income
$-96.1M
46.94%
Profit margin
0%
-

Opthea Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 54.18%
QuarterlyAnnual
Q2 22
Q4 23
Q2 23
Q4 24
Q2 24
Actual
-$1.74
-$1.97
-$1.86
-$1.30
-
Expected
-$0.19
-$0.13
-$0.24
-$0.84
-$1.14
Surprise
824.32%
1,413.85%
678.68%
54.18%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
ADR

Upcoming events

FAQs

What’s the current market cap for Opthea stock?

Opthea (OPT) has a market cap of $268.66M as of April 21, 2024.

What is the P/E ratio for Opthea stock?

The price to earnings (P/E) ratio for Opthea (OPT) stock is 0 as of April 21, 2024.

Does Opthea stock pay dividends?

No, Opthea (OPT) stock does not pay dividends to its shareholders as of April 21, 2024.

When is the next Opthea dividend payment date?

Opthea (OPT) stock does not pay dividends to its shareholders.

What is the beta indicator for Opthea?

Opthea (OPT) has a beta rating of 0.62. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Opthea stock price target?

The target price for Opthea (OPT) stock is $12.8, which is 287.88% above the current price of $3.3. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Opthea stock

Buy or sell Opthea stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing